These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29708404)

  • 1. BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma.
    Lukas RV; Merrell RT
    CNS Oncol; 2018 Apr; 7(2):CNS10. PubMed ID: 29708404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage therapy with BRAF inhibitors for recurrent pleomorphic xanthoastrocytoma: a retrospective case series.
    Chamberlain MC
    J Neurooncol; 2013 Sep; 114(2):237-40. PubMed ID: 23756728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.
    Brown NF; Carter T; Mulholland P
    CNS Oncol; 2017 Jan; 6(1):5-9. PubMed ID: 27781490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful Treatment of a Progressive BRAF V600E-Mutated Anaplastic Pleomorphic Xanthoastrocytoma With Vemurafenib Monotherapy.
    Lee EQ; Ruland S; LeBoeuf NR; Wen PY; Santagata S
    J Clin Oncol; 2016 Apr; 34(10):e87-9. PubMed ID: 25092772
    [No Abstract]   [Full Text] [Related]  

  • 5. Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib.
    van Tilburg CM; Selt F; Sahm F; Bächli H; Pfister SM; Witt O; Milde T
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29230924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to BRAF/MEK Inhibition After Progression With BRAF Inhibition in a Patient With Anaplastic Pleomorphic Xanthoastrocytoma.
    Hussain F; Horbinski CM; Chmura SJ; Yamini B; Lukas RV
    Neurologist; 2018 Sep; 23(5):163-166. PubMed ID: 30169370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Anaplastic pleomorphic xanthoastrocytoma - single-center analysis of 42 patients].
    Belyaev AY; Shugai SV; Kobyakov GL; Strunina YV; Batalov AI; Pronin IN; Usachev DY
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(2):45-54. PubMed ID: 35412712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab, irinotecan, temozolomide, tyrosine kinase inhibition, and MEK inhibition are effective against pleomorphic xanthoastrocytoma regardless of V600E status.
    Thompson EM; Landi D; Ashley D; Keir ST; Bigner D
    J Neurooncol; 2018 Nov; 140(2):261-268. PubMed ID: 30120661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Efficacy of Single-agent Vemurafenib for Pleomorphic Xanthoastrocytoma.
    Finch EA; Elton SW; Huang BY; Trembath DG; Blatt J
    J Pediatr Hematol Oncol; 2020 Mar; 42(2):152-155. PubMed ID: 30601402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma.
    Amayiri N; Swaidan M; Al-Hussaini M; Halalsheh H; Al-Nassan A; Musharbash A; Tabori U; Hawkins C; Bouffet E
    J Pediatr Hematol Oncol; 2018 Aug; 40(6):478-482. PubMed ID: 29200156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of
    Huang W; Cai J; Lin N; Xu Y; Wang H; Wu Z; Kang D
    AJNR Am J Neuroradiol; 2021 Dec; 42(12):2152-2159. PubMed ID: 34725042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma.
    Pratt D; Camelo-Piragua S; McFadden K; Leung D; Mody R; Chinnaiyan A; Koschmann C; Venneti S
    Acta Neuropathol Commun; 2018 Mar; 6(1):24. PubMed ID: 29544532
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined pleomorphic xanthoastrocytoma-ganglioglioma with BRAF V600E mutation: case report.
    Cicuendez M; Martinez-Saez E; Martinez-Ricarte F; Asanza EC; Sahuquillo J
    J Neurosurg Pediatr; 2016 Jul; 18(1):53-7. PubMed ID: 27015517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unprecedented response to combination BRAF and MEK inhibitors in adult anaplastic ganglioglioma.
    Beland B; Tsang RY; Sutherland G
    J Neurooncol; 2018 May; 137(3):667-669. PubMed ID: 29335912
    [No Abstract]   [Full Text] [Related]  

  • 15. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
    Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
    Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare clinical presentations of pleomorphic xanthoastrocytoma with a high proliferative index: Two case reports.
    Nagaishi M; Nakae R; Fujii Y; Inoue Y; Sugiura Y; Takano I; Tanaka Y; Suzuki K
    Medicine (Baltimore); 2020 Jan; 99(3):e18880. PubMed ID: 32011515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleomorphic xanthoastrocytoma in the brainstem with BRAF V600E mutation: A case report.
    Guo Y; Ning G; Feng M; Qu HB
    Asian J Surg; 2023 Aug; 46(8):3371-3373. PubMed ID: 36977615
    [No Abstract]   [Full Text] [Related]  

  • 18. A Rare Case of BRAF-mutated Metastatic Pleomorphic Xanthoastrocytoma Patient who Developed Radiodermatitis After Receiving Anti-BRAF Treatment.
    Atahan C; Arslantas E; Ersen Danyeli A; Celik L; Bozkurt G; Ugurluer G; Corapcioglu FV; Ozyar E
    J Pediatr Hematol Oncol; 2023 Nov; 45(8):e1005-e1009. PubMed ID: 37700448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.
    Bautista F; Paci A; Minard-Colin V; Dufour C; Grill J; Lacroix L; Varlet P; Valteau-Couanet D; Geoerger B
    Pediatr Blood Cancer; 2014 Jun; 61(6):1101-3. PubMed ID: 24375920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF-Mutated Pleomorphic Xanthoastrocytoma of the Spinal Cord with Eventual Anaplastic Transformation.
    Hong CS; Wang JL; Dornbos D; Joehlin-Price A; Elder JB
    World Neurosurg; 2017 Feb; 98():871.e9-871.e15. PubMed ID: 27956254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.